Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
纳武利尤单抗联合伊匹木单抗对比舒尼替尼一线治疗晚期肾细胞癌：一项随机、对照、3期试验的疗效和安全性结果的长期随访
期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(19)30413-9
Motzer, Robert J; Rini, Brian I; McDermott, David F; Arén Frontera, Osvaldo; Hammers, Hans J; Carducci, Michael A; Salman, Pamela; Escudier, Bernard; Beuselinck, Benoit; Amin, Asim; Porta, Camillo; George, Saby; Neiman, Victoria; Bracarda, Sergio; Tykodi, Scott S; Barthélémy, Philippe; Leibowitz-Amit, Raya; Plimack, Elizabeth R; Oosting, Sjoukje F; Redman, Bruce; Melichar, Bohuslav; Powles, Thomas; Nathan, Paul; Oudard, Stéphane; Pook, David; Choueiri, Toni K; Donskov, Frede; Grimm, Marc-Oliver; Gurney, Howard; Heng, Daniel Y C; Kollmannsberger, Christian K; Harrison, Michael R; Tomita, Yoshihiko; Duran, Ignacio; Grünwald, Viktor; McHenry, M Brent; Mekan, Sabeen; Tannir, Nizar M
